+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Efficacy and prognosis analysis in 188 children with acute lymphoblastic leukemia of China



Efficacy and prognosis analysis in 188 children with acute lymphoblastic leukemia of China



Zhonghua Er Ke Za Zhi 46(7): 498-501



To analyze the therapeutic effect and the influencing factors of event-free survival (EFS) of childhood acute lymphoblastic leukemia (ALL) in Xiangya Hospital of Central South University and the First Affiliated Hospital of Guangxi Medical University. All the patients adopted chemotherapy according to therapeutic guideline revised by the Subspecialty Group of Hematology, The Society of Pediatrics, Chinese Medical Association for the second-time in 1998 (the Rongcheng ALL-98 Protocol). Kaplan-Meier method was used to estimate the survival rates of 188 patients who received therapy with good compliance. The differences of EFS between groups were assessed by Log-rank test. The independent influencing factors on EFS were analyzed by the Cox proportional hazards regression model. After receiving inductive treatment, 354 of 374 (93.6%) patients demonstrated a complete remission; 188 patients who received complete courses of treatment with good compliance showed (68.1 +/- 5.6)% five-year EFS. Meanwhile, the five-year EFS in standard-risk (SR) group and high-risk (HR) group were (75.2 +/- 6.0)% and (47.6 +/- 11.6)%, respectively. The total relapse rate was 10.6% and the median time to relapse was 13 months. Twenty-nine of 188 patients (15.4%) were dead, and 13 patients (7.0%) died from treatment-related complications. Independent adverse prognostic factors included risk grouping, t (9; 22)/bcr-abl gene and leukocyte count. The total EFS of childhood ALL patients treated with Rongcheng ALL-98 Protocol in two hospitals was close to 70%. Therefore, it is necessary to evaluate risk factors and consider the grouping in more detail to reduce the treatment-related mortality and to increase the compliance of treatment which can ultimately improve the EFS.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 052894944

Download citation: RISBibTeXText

PMID: 19099804


Related references

Impact of treatment efficacy on the prognosis of Black children with acute lymphoblastic leukemia. Blood 82(10 Suppl. 1): 55A, 1993

Methotrexate infusions in poor prognosis acute lymphoblastic leukemia in children: I. The Norwegian methotrexate study in acute lymphoblastic leukemia in childhood, August 1975-December 1980. Medical and Pediatric Oncology 14(3): 187-188, 1986

Analysis of multicenter efficacy of acute lymphoblastic leukemia in older children. Zhonghua Xue Ye Xue Za Zhi 34(7): 581-586, 2013

IKZF1 deletions predict a poor prognosis in children with B-cell progenitor acute lymphoblastic leukemia: a multicenter analysis in Taiwan. Cancer Science 102(10): 1874-1881, 2011

The results of a multicenter trial of acute lymphoblastic leukemia treatment on ALL-MB 91/ALL-BFM 90m in children: analysis of efficacy and toxicity. Terapevticheskii Arkhiv 79(7): 19-26, 2007

Studies on the initial features and prognosis in 21 infants with acute lymphoblastic leukemia. Children's Cancer and Leukemia Study Group. Japanese Journal of Clinical Hematology 28(5): 721-729, 1987

Prognosis and DNA aneuploidy in children with acute lymphoblastic leukemia. Haematology and Blood Transfusion 33: 174-181, 1990

Sex differences in prognosis for children with acute lymphoblastic leukemia. Journal of Clinical Oncology 17(3): 818-824, 1999

Prognosis and development of acute lymphoblastic leukemia in children. La Revue du Praticien 36(37): 2171-2178, 1986

Prognosis in 592 turkish children with acute lymphoblastic leukemia. European Journal of Pediatrics 146(3): 321, 1987

Long-term prognosis in 139 children with acute lymphoblastic leukemia in complete remission for longer than three years--study of Children's Cancer and Leukemia Study Group. Japanese Journal of Clinical Hematology 28(2): 177-186, 1987

Expert consensus on adult acute lymphoblastic leukemia in China-interpretation of diagnosis and prognosis stratification. Zhonghua Xue Ye Xue Za Zhi 34(11): 994-996, 2013

Pediatric Acute Lymphoblastic Leukemia: Efficacy and safety of recombinant E. coli-asparaginase in infants (less than one year of age) with acute lymphoblastic leukemia. Haematologica 98(11): 1697-1701, 2013

Soluble Fas and Fas ligand and prognosis in children with acute lymphoblastic leukemia. Medical Oncology 29(3): 2046-2052, 2012